Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières, Tom Waddell, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L. Rhoda Molife, Michael B. Atkins, Brian I. Rini